{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:23:06Z","timestamp":1785936186831,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":202,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.curtheres.2025.100809","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T23:15:47Z","timestamp":1753312547000},"page":"100809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Initiation of Type 2 Diabetes Mellitus Medications in the NGHA Healthcare System in Saudi Arabia: Contemporary Trends"],"prefix":"10.1016","volume":"103","author":[{"given":"Mesnad S.","family":"Alyabsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lolwah","family":"Almousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar H.","family":"Alqarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Aldawsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Alnasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel F.","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.curtheres.2025.100809_bib0001","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes-global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"key":"10.1016\/j.curtheres.2025.100809_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.curtheres.2025.100809_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/sjmms.sjmms_394_22","article-title":"Prevalence of type 2 diabetes mellitus in the general population of Saudi Arabia, 2000\u20132020: a systematic review and meta-analysis of observational studies","volume":"11","author":"Jarrar","year":"2023","journal-title":"Saudi J Med Sci"},{"issue":"4","key":"10.1016\/j.curtheres.2025.100809_bib0004","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2174\/1573399811666150724095130","article-title":"Diabetes mellitus in Saudi Arabia: a review of the recent literature","volume":"12","author":"Abdulaziz Al Dawish","year":"2016","journal-title":"Curr Diabetes Rev"},{"issue":"2","key":"10.1016\/j.curtheres.2025.100809_bib0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1570161117666190502103733","article-title":"Microvascular complications of type 2 diabetes mellitus","volume":"18","author":"Faselis","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.curtheres.2025.100809_bib0006","author":"Richardson","year":"2021","journal-title":"Management of Type 2 Diabetes Mellitus"},{"key":"10.1016\/j.curtheres.2025.100809_bib0007","doi-asserted-by":"crossref","unstructured":"Genuth S. Should Sulfonylureas remain an acceptable first-line add-on to Metformin therapy in patients with type 2 diabetes? No, it\u2019s time to move on! diabetes care. 2015;38(1):170-175. doi:10.2337\/dc14-0565","DOI":"10.2337\/dc14-0565"},{"issue":"Supplement_1","key":"10.1016\/j.curtheres.2025.100809_bib0008","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc24-SINT","article-title":"Introduction and methodology: standards of care in diabetes\u20142024","volume":"47","author":"Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.curtheres.2025.100809_bib0009","article-title":"Oral and injectable (Non-Insulin) pharmacological agents for the treatment of type 2 diabetes","author":"Feingold","year":"2024","journal-title":"Endotext"},{"issue":"8","key":"10.1016\/j.curtheres.2025.100809_bib0012","first-page":"322","article-title":"SGLT2 Inhibitors vs. GLP-1 antagonists to treat the heart, the kidneys and the brain","volume":"10","author":"Rolek","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"3","key":"10.1016\/j.curtheres.2025.100809_bib0013","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.2016.9400","article-title":"Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: A meta-analysis","volume":"316","author":"Palmer","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.curtheres.2025.100809_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2022-002995","article-title":"Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada","volume":"10","author":"Carney","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"8","key":"10.1016\/j.curtheres.2025.100809_bib0015","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2337\/dc20-2926","article-title":"Trends in first-line glucose-lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA","volume":"44","author":"Shin","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.curtheres.2025.100809_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111781","article-title":"Profiles of Sulfonylurea use in Diabetes mellitus type 2: an analysis of clinical practice over the last 10 years","volume":"214","author":"Baccetti","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"10.1016\/j.curtheres.2025.100809_bib0017","first-page":"2009","article-title":"Trends in the use of sulfonylurea types among US adults with diabetes: NHANES 1999\u20132020","volume":"38","author":"Shin","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2025.100809_bib0018","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021","volume":"44","author":"Association","year":"2021","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.curtheres.2025.100809_bib0019","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.2337\/dc22-0224","article-title":"Trends in prescription preferences for antidiabetic medications among patients with type 2 diabetes in the U.K. with and without chronic kidney disease, 2006\u20132020","volume":"45","author":"Liaw","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.curtheres.2025.100809_bib0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2337\/diaspect.27.2.82","article-title":"A brief history of the development of diabetes medications","volume":"27","author":"White","year":"2014","journal-title":"Diabetes Spectr"},{"issue":"6","key":"10.1016\/j.curtheres.2025.100809_bib0022","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/fcp.12298","article-title":"Trends in the incidence of use of noninsulin glucose-lowering drugs between 2006 and 2013 in France","volume":"31","author":"Arnaud","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.curtheres.2025.100809_bib0023","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clinthera.2017.02.008","article-title":"Type 2 diabetes mellitus treatment patterns across Europe: A population-based multi-database study","volume":"39","author":"Overbeek","year":"2017","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.curtheres.2025.100809_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025806","article-title":"Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: A claims-based cohort study","volume":"9","author":"Nishimura","year":"2019","journal-title":"BMJ Open"},{"issue":"9131","key":"10.1016\/j.curtheres.2025.100809_bib0025","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"Turner","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.curtheres.2025.100809_bib0026","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/00325481.2015.1043182","article-title":"Revisiting weight reduction and management in the diabetic patient: novel therapies provide new strategies","volume":"127","author":"Schwartz","year":"2015","journal-title":"Postgrad Med"},{"key":"10.1016\/j.curtheres.2025.100809_bib0021","article-title":"Approves new drug treatment for chronic weight management","author":"FDA","year":"2022","journal-title":"FDA Drug Saf Commun"},{"issue":"4","key":"10.1016\/j.curtheres.2025.100809_bib0027","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and the progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.curtheres.2025.100809_bib0028","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.curtheres.2025.100809_bib0029","first-page":"101","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"54","author":"Marso","year":"2016","journal-title":"Drug Ther Bull"},{"key":"10.1016\/j.curtheres.2025.100809_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111770","article-title":"Treatment modification patterns of glucose-lowering agents in Saudi Arabia: A retrospective real-world data analysis","volume":"214","author":"Alfakhri","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.curtheres.2025.100809_bib0031","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s13300-024-01556-z","article-title":"Expert opinion on current trends in the use of insulin in the management of people with type 2 diabetes from the Southeast European Region and Israel","volume":"15","author":"Tabak","year":"2024","journal-title":"Diabetes Ther"},{"issue":"9","key":"10.1016\/j.curtheres.2025.100809_bib0032","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1089\/dia.2013.0081","article-title":"Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes","volume":"15","author":"Owens","year":"2013","journal-title":"Diabetes Technol Ther"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X25000347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X25000347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:13:50Z","timestamp":1765358030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X25000347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":30,"alternative-id":["S0011393X25000347"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2025.100809","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiation of Type 2 Diabetes Mellitus Medications in the NGHA Healthcare System in Saudi Arabia: Contemporary Trends","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2025.100809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100809"}}